Checkpoint Therapeutics Inc.
| NASDAQ: CKPT | Healthcare / Biotechnology / USA |
| 1.75 | +0.1401 | +8.70% | Vol 343.26K | 1Y Perf 50.47% |
| Oct 3rd, 2023 15:34 DELAYED |
| BID | 1.74 | ASK | 1.76 | ||
| Open | 1.58 | Previous Close | 1.61 | ||
| Pre-Market | 1.62 | After-Market | - | ||
| 0.01 0.62% | - - |
| Target Price | 159.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 8.99K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.41 | Earnings Rating | Strong Sell | |
| Market Cap | 37.79M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.24 | |
| Beta | 1.41 |
Today's Price Range 1.581.80 | 52W Range 1.3011.50 | 5 Year PE Ratio Range -5.40-4.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 15.83% | ||
| 1 Month | -21.08% | ||
| 3 Months | -35.60% | ||
| 6 Months | -36.86% | ||
| 1 Year | 50.47% | ||
| 3 Years | -39.02% | ||
| 5 Years | -51.51% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -93.57 | |||
ROE last 12 Months | -363.13 | |||
ROA (5Y Avg) | -39.83 | |||
ROA last 12 Months | -194.78 | |||
ROC (5Y Avg) | -138.51 | |||
ROC last 12 Months | -306.47 | |||
Return on invested Capital Q | -348.10 | |||
Return on invested Capital Y | -76.61 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 3.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.70 | ||||
| 8.56 | ||||
| 548.83 | ||||
| - | ||||
| -1.60 | ||||
| -6.07 | ||||
| -49.22 | ||||
| -0.13 | ||||
| 45.24M | ||||
| Forward PE | -3.95 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.90 | ||||
| 0.90 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 3.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -53 327.60 | ||||
| -53 327.60 | ||||
| -38 386.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 118.00K | ||||
| 0.01 | ||||
| -53.93 | ||||
| -34.98 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.83 | -1.05 | -26.51 |
| Q01 2023 | -0.92 | -0.89 | 3.26 |
| Q03 2022 | -1.70 | -1.20 | 29.41 |
| Q02 2022 | -1.70 | -1.60 | 5.88 |
| Q01 2022 | -1.10 | -2.00 | -81.82 |
| Q04 2021 | -1.40 | -3.90 | -178.57 |
| Q03 2021 | -1.30 | -1.40 | -7.69 |
| Q02 2021 | -0.09 | -0.12 | -33.33 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.85 | -10.39 | Negative |
| 12/2023 QR | -0.95 | -17.28 | Negative |
| 12/2023 FY | -3.40 | -5.26 | Negative |
| 12/2024 FY | -0.43 | 8.51 | Positive |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -0.85 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 343.26K |
| Shares Outstanding | 21.59K |
| Shares Float | 18.35M |
| Trades Count | 1.53K |
| Dollar Volume | 589.03K |
| Avg. Volume | 257.90K |
| Avg. Weekly Volume | 273.14K |
| Avg. Monthly Volume | 228.61K |
| Avg. Quarterly Volume | 271.95K |
Checkpoint Therapeutics Inc. (NASDAQ: CKPT) stock closed at 1.61 per share at the end of the most recent trading day (a -5.29% change compared to the prior day closing price) with a volume of 343.72K shares and market capitalization of 37.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Checkpoint Therapeutics Inc. CEO is James F. Oliviero.
The one-year performance of Checkpoint Therapeutics Inc. stock is 50.47%, while year-to-date (YTD) performance is -68.49%. CKPT stock has a five-year performance of -51.51%. Its 52-week range is between 1.3 and 11.5, which gives CKPT stock a 52-week price range ratio of 4.41%
Checkpoint Therapeutics Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 8.56, a price-to-sale (PS) ratio of 548.83, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -194.78%, a ROC of -306.47% and a ROE of -363.13%. The company’s profit margin is -%, its EBITDA margin is -53 327.60%, and its revenue ttm is $118.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from Checkpoint Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.85 for the next earnings report. Checkpoint Therapeutics Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Checkpoint Therapeutics Inc. is Strong Buy (1), with a target price of $159, which is +8 985.20% compared to the current price. The earnings rating for Checkpoint Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Checkpoint Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Checkpoint Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.25, ATR14 : 0.17, CCI20 : -53.97, Chaikin Money Flow : -0.15, MACD : -0.16, Money Flow Index : 29.57, ROC : -18.27, RSI : 39.14, STOCH (14,3) : 40.26, STOCH RSI : 0.84, UO : 45.90, Williams %R : -59.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Checkpoint Therapeutics Inc. in the last 12-months were: James F. Oliviero (Sold 28 926 shares of value $153 684 ), William Garrett Gray (Sold 1 858 shares of value $12 540 )
Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
CEO: James F. Oliviero
Telephone: +1 781 652-4500
Address: 2 Gansevoort Street, New York 10014, NY, US
Number of employees: 8
